{"prompt": "['completed the 12 week treatment period. One patient discontinued the treatment and moved', 'to the post discontinuation follow up period. A total of 16 of the 17 patients who completed', 'the 12 week treatment period subsequently enrolled into extension Study ACE002JP, and', 'one patient moved to the post treatment observation period of Study ACE001JP Thus,', 'which includes six patients from the 0.3 mg/kg/week group, five patients from the', '1 mg/kg/week group, and five patients from the 3 mg/kg/week group of Study ACE001JP', 'The duration of follow-up for the patients in the 0.3, 1, and 3 mg/kg/week cohorts who', 'enrolled in Study ACE002JP ranges from 140 to 145, 116 to 124, and 89 to 98 weeks,', 'respectively (cut-off date 15th February 2016). For Studies ACE001JP and ACE002JP, the', 'efficacy parameter of annualized bleeding rate (ABR) has been calculated by annualizing the', 'number of bleeds that required treatment with coagulation factor products during the', '6 months prior to study enrollment and during the treatment period after the first emicizumab', 'administration. During the 6 months before study enrollment, the patients without inhibitors', 'received FVIII prophylactic replacement therapy, while the patients with inhibitors received', 'episodic therapy and/or prophylactic therapy with bypassing agents.', 'After administration of emicizumab to patients with hemophilia A, annualized bleeding rates', '(ABRs) decreased in all patients in Studies ACE001JP and ACE002JP compared with the', 'pre-treatment period, regardless of whether or not they had FVIII inhibitors, with the', 'exception of one patient in the 3 mg/kg/week group who was previously treated with FVIII', 'prophylaxis and had a baseline ABR of 0 (in this patient, the ABR was maintained at 0 while', 'receiving emicizumab). Among all patients, percentage reduction in ABR ranged from 22.8%', 'to 100% in the 0.3 mg/kg/week group, from 57.5% to 100% in the 1 mg/kg/week group, and', 'from 90.1% to 100% in the 3 mg/kg/week group.', 'The safety data from completed studies of healthy male volunteers (Japanese and Caucasian) in', 'ACE001JP Parts A and B (n=48) showed that emicizumab was well tolerated and the incidence of', 'adverse events was similar in the emicizumab dosing groups and the placebo group. Moreover, no', 'racial differences or dose-dependent increases in the incidence of adverse events were observed. There', 'were no serious adverse events, adverse events leading to discontinuation, or deaths in either study.', 'From ACE001JP Part C and its ongoing extension ACE002JP (as of the cut-off date 15 February', '2016), most adverse events were of mild or moderate intensity, except for 2 severe adverse events', '(appendicitis and mesenteric hematoma). The majority of the adverse events were not considered', \"related to emicizumab (see the Emicizumab Investigator's Brochure).\", '1.2.2.2', 'JP29574', 'Completed Study JP29574 included 5 groups of 12 healthy Japanese volunteers. This study', 'investigated the relative bioavailability between Phase I/II 80 mg/mL formulation and Phase III 150', 'mg/mL formulation materials and among three different sites of injection, as well as the absolute', 'bioavailability. Results showed no significant difference in the incidence of adverse events observed by', 'formulation, injection site, or administration route.', 'Emicizumab has been well tolerated in patients in the Phase I/II studies (cut-off date 15th', \"February 2016; see the emicizumab Investigator's Brochure). The majority of adverse events\", 'have been mild in intensity, except for five moderate adverse events (upper respiratory tract', 'Emicizumab - F. Hoffmann-La Roche Ltd', '10 / Protocol MO39129, Version 3']['infection, bipolar I disorder, hemophilia [left hip joint bleeding due to hemophilia], headache,', 'and asthma) and two severe adverse events (appendicitis and mesenteric hematoma). Both', 'severe events were considered to be serious adverse events and not related to emicizumab', 'administration. A total of seven patients have reported injection-site reactions (including', 'erythema, hematoma, rash, pain, discomfort, and pruritus). All injection-site reactions were', 'mild in intensity. Besides injection-site reactions, the most frequently reported adverse', 'events (at least four patients) have been nasopharyngitis, pharyngitis, dental caries,', 'excoriation, and headache. There have not been any dose-dependent increases in adverse', 'events, and the majority of the adverse events have not been considered to be related to', 'emicizumab. Treatment was discontinued for one patient with injection-site erythema in the', '1 mg/kg weekly group; the event was mild in intensity and resolved. The same patient also', 'reported one non-related serious adverse event (hemophilia [left hip joint bleeding due to', 'hemophilia]) approximately 24 weeks after the last dose of study drug. In the Phase I/II', 'studies, no thromboembolic adverse events have been reported when emicizumab has been', 'administered alone or concomitantly with FVIII products or bypassing agents as episodic', 'therapy.', '1.2.2.3', 'Studies BH29884 and BH29992', 'The ongoing Phase III study (BH29884) is enrolling patients with hemophilia A aged', '12 years or older who have inhibitors against FVIII and have received episodie or', 'prophylactic treatment with bypassing agents prior to study entry.', 'As of October 2016, thrombotic microangiopathy (TMA) has been observed in two patients', 'receiving emicizumab and bypassing agents see Section 5.1.1.3) and two cases of', 'thromboembolic events have been observed in two patients receiving the same regimen', '(see Section 5.1.1.2).', 'The HAVEN 1 study (BH29884; NCT02622321) was a randomized, multicenter, open-label, clinical', 'trial in 109 adult and adolescent males (aged 12 to 75 years and > 40 kg) with hemophilia A with', 'FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with', 'bypassing agents. Patients received weekly emicizumab prophylaxis (Arms A, C, and D), 3 mg/kg', 'once weekly for the first 4 weeks followed by 1.5 mg/kg once weekly thereafter, or no prophylaxis', '(Arm B). Dose up-titration to 3 mg/kg once weekly was allowed after 24 weeks on emicizumab', 'prophylaxis in case of suboptimal efficacy (i.e., 2 spontaneous and clinically significant bleeds).', 'During the study, two patients underwent up-titration of their maintenance dose to 3 mg/kg once', 'weekly.', 'Fifty-three patients previously treated with episodic (on-demand) bypassing agents were randomized', 'in a 2:1 ratio to receive emicizumab prophylaxis (Arm A) or no prophylaxis (Arm B), with', 'stratification by prior 24-week bleed rate (< 9 or 9). Patients randomized to Arm B could switch to', 'emicizumab prophylaxis after completing at least 24 weeks without prophylaxis.', 'Forty-nine patients previously treated with prophylactic bypassing agents were enrolled into Arm', 'C', 'to receive emicizumab prophylaxis. Seven patients previously treated with episodic (on-demand)', 'bypassing agents who had participated in a non-interventional study (NIS) prior to enrollment, but', 'Emicizumab - F. Hoffmann-La Roche Ltd', '11 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}